The dramatic effectiveness of electroconvulsive therapy comes with a sobering reality: roughly half of patients who achieve remission from severe depression will relapse within twelve months without proper maintenance strategies. This creates a critical window where the gains from one of psychiatry's most potent treatments can evaporate, leaving patients vulnerable to recurring episodes that may prove even more treatment-resistant.
A comprehensive analysis of 28 studies encompassing over 11,000 patients reveals that lithium emerges as the most consistently protective intervention, whether used alone or combined with antidepressants across ten separate investigations. Continuation ECT sessions, particularly when paired with pharmacological support, demonstrated significant relapse reduction in multiple randomized trials. The research landscape shows notable gaps, with only two studies examining psychotherapy approaches like cognitive-behavioral therapy, and complete absence of data on newer interventions such as repetitive transcranial magnetic stimulation or ketamine maintenance protocols.
This evidence synthesis highlights a fundamental challenge in modern psychiatry: while acute treatment protocols for severe depression are increasingly sophisticated, maintenance strategies remain underdeveloped. The 50% relapse rate represents not just statistical failure but profound human suffering, given that patients requiring ECT typically have treatment-resistant depression with high suicide risk. The consistent lithium findings suggest this decades-old mood stabilizer deserves renewed attention in post-ECT protocols, while the limited psychotherapy data reveals a significant research blind spot. For clinicians managing post-ECT patients, these findings advocate for aggressive maintenance approaches combining pharmacological and neuromodulatory strategies rather than hoping remission will naturally sustain itself.